Aliskiren: Phase III data

In the double-blind, placebo-controlled Phase III A2308 trial, 150, 300 and 600 mg of Aliskiren (SPP100) monotherapy significantly reduced blood pressure vs. placebo (p<0.0001). The response rates wer...